Highlights

  • ReNerve raises AUD 3.2M through a two-tranche placement at a discounted offer price.
  • Funds allocated to sales expansion, new product development, and working capital needs.
  • Shareholder approval required for Tranche 2 issuance and attaching options.

ReNerve Limited (ASX:RNV) reported that it has secured commitments from institutional and sophisticated investors to raise approximately AUD 3.2M before costs. The capital raise involves issuing around 26,666,667 fully paid ordinary shares at an offer price of AUD 0.12 per share. The pricing reflects a 22.6% discount to the company’s last closing share price on 17 November 2025 and a 28.2% discount to the 15-day volume-weighted average price.

The placement is divided into two tranches. Tranche 1 is structured to raise approximately AUD 2.6M through the issue of 21,581,587 new shares. These shares are being issued under the company’s existing placement capacity pursuant to ASX Listing Rule 7.1.
Tranche 2 is designed to raise approximately AUD 0.6M via the issue of 5,085,080 shares. This tranche is conditional on shareholder approval at an Extraordinary General Meeting expected to take place on 5 January 2026.

Attaching Options and Shareholder Approvals

Both tranches include one-for-one free attaching options, amounting to a total of 26,666,667 new options. These options carry an exercise price of AUD 0.18 and a maturity period of two years from the date of issue. The issuance of all attaching options is subject to approval at the upcoming EGM.
The shares under Tranche 1 will be quoted and traded following their intended issue on 1 December 2025, while Tranche 2 shares will proceed to quotation after shareholder approval.

Use of Placement Funds

The company stated that proceeds from the placement will support several operational and development activities. These include expanding sales and marketing programs for the company’s existing product ranges, including NervAlign and EmpliQ, as well as advancing new product developments such as nerve conduit products and a nerve guide matrix. Additional funding will be allocated toward strengthening the sales team and providing working capital for ongoing operations.

Indicative Timetable for Completion

The indicative timeline released by the company outlines key dates, beginning with the announcement of the placement and the lifting of the trading halt on 20 November 2025. Settlement of Tranche 1 shares is expected on 28 November 2025, with the issue and quotation of these shares scheduled for 1 December 2025. The EGM, settlement, quotation, and trading of Tranche 2 shares are targeted for 5 January 2026.

Share Price Snapshot

RNV was trading 25.80% higher at AUD 0.115 per share as of 20 November 2025.